RESPECT: Observational, Prospective, Open-Label, Multi-Center Study Evaluating the Antihypertensive Effect of Treatment With Telmisartan (Alone or in Fixed Combination With HCTZ) in General Practitioner and Specialist Practice in Hypertensive Patients With High and Very High Cardiovascular Risk According to the ESH/ESC Guidelines 2007 Who Are Uncontrolled Under Current Treatment.

Trial Profile

RESPECT: Observational, Prospective, Open-Label, Multi-Center Study Evaluating the Antihypertensive Effect of Treatment With Telmisartan (Alone or in Fixed Combination With HCTZ) in General Practitioner and Specialist Practice in Hypertensive Patients With High and Very High Cardiovascular Risk According to the ESH/ESC Guidelines 2007 Who Are Uncontrolled Under Current Treatment.

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jun 2014

At a glance

  • Drugs Telmisartan (Primary) ; Telmisartan/hydrochlorothiazide (Primary)
  • Indications Hypertension
  • Focus Therapeutic Use
  • Acronyms RESPECT
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 01 May 2012 Actual patient number changed from 16 to 2913 as reported by ClinicalTrials.gov.
    • 15 Jan 2010 Actual end date (Dec 2009) and actual number of patients (16) added as reported by ClinicalTrials.gov.
    • 15 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top